[SCHEDULE 13G] BTC Digital Ltd. SEC Filing
On 07/15/2025, CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. jointly filed a Schedule 13G reporting a passive ownership of 1,000,000 BriaCell Therapeutics Corp. common shares (CUSIP 107930208). The stake equals 5.7 % of the 17.55 M shares outstanding, as cited in BriaCell鈥檚 July 2025 prospectus. Each Reporting Person claims 0 sole and 1,000,000 shared voting and dispositive power. Both entities disclaim beneficial ownership beyond their pecuniary interest and certify the shares were not acquired to influence control. Signatory: Sarah Travis (Heights Capital) on 07/22/2025. No group arrangements, subsidiaries, or additional controlling interests are disclosed.
Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G dichiarando una posizione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La partecipazione rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ogni soggetto dichiarante detiene 0 poteri di voto e disposizione esclusivi e 1.000.000 condivisi. Entrambe le entit脿 escludono la propriet脿 effettiva oltre il loro interesse economico e certificano che le azioni non sono state acquisite per influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o altri interessi di controllo.
El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una posesi贸n pasiva de 1,000,000 acciones ordinarias de BriaCell Therapeutics Corp. (CUSIP 107930208). La participaci贸n equivale al 5.7% de las 17.55 millones de acciones en circulaci贸n, seg煤n el prospecto de BriaCell de julio de 2025. Cada persona informante declara 0 poder de voto y disposici贸n exclusivo y 1,000,000 compartidos. Ambas entidades niegan la propiedad beneficiaria m谩s all谩 de su inter茅s econ贸mico y certifican que las acciones no fueron adquiridas para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se revelan arreglos grupales, subsidiarias ni otros intereses de control adicionales.
2025雲� 7鞗� 15鞚�, CVI Investments, Inc.鞕赌 韴瀽 甏�毽瀽 Heights Capital Management, Inc.電� 瓿惦彊鞙茧 Schedule 13G毳� 鞝滌稖頃橃棳 1,000,000欤� BriaCell Therapeutics Corp. 氤错喌欤� (CUSIP 107930208)鞐� 雽�頃� 靾橂彊鞝� 靻岇湢甓�鞚� 氤搓碃頄堨姷雼堧嫟. 鞚� 歆�攵勳潃 BriaCell鞚� 2025雲� 7鞗� 韴瀽靹る獏靹滌棎 氇呾嫓霅� 17.55氚彪 欤� 欷� 5.7%鞐� 頃措嫻頃╇媹雼�. 臧� 氤搓碃鞛愲姅 雼弲 韴憸 氚� 觳橂秳 甓岉暅 0欤�鞕赌 瓿惦彊 韴憸 氚� 觳橂秳 甓岉暅 1,000,000欤�毳� 欤检灔頃╇媹雼�. 鞏� 旮瓣磤鞚� 旮堨爠鞝� 鞚挫澋鞚� 齑堦臣頃橂姅 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙晿氅�, 欤检嫕鞚� 歆�氚瓣秾 鞓來枼鞚� 氇╈爜鞙茧 旆摑霅橃 鞎婌晿鞚岇潉 鞚胳頃╇媹雼�. 靹滊獏鞛�: Sarah Travis (Heights Capital), 2025雲� 7鞗� 22鞚�. 攴鸽９ 順戩暯, 鞛愴殞靷� 霕愲姅 於旉皜 歆�氚瓣秾鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d'investissement Heights Capital Management, Inc. ont conjointement d茅pos茅 un Schedule 13G d茅clarant une participation passive de 1 000 000 actions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation repr茅sente 5,7 % des 17,55 millions d'actions en circulation, comme indiqu茅 dans le prospectus de BriaCell de juillet 2025. Chaque personne d茅clarante revendique 0 pouvoir de vote et de disposition exclusif et 1 000 000 partag茅. Les deux entit茅s d茅clinent toute propri茅t茅 b茅n茅ficiaire au-del脿 de leur int茅r锚t p茅cuniaire et certifient que les actions n'ont pas 茅t茅 acquises pour influencer le contr么le. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiale ou autre int茅r锚t de contr么le n鈥檈st divulgu茅.
Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein, in dem ein passives Eigentum von 1.000.000 BriaCell Therapeutics Corp. Stammaktien (CUSIP 107930208) gemeldet wurde. Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 ver枚ffentlichten Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verf眉gungsrechte. Beide Einheiten lehnen eine wirtschaftliche Eigent眉merschaft 眉ber ihr finanzielles Interesse hinaus ab und best盲tigen, dass die Aktien nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden. Unterzeichnerin: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.
- Institutional ownership disclosed: CVI Investments & Heights Capital now publicly report a 5.7 % stake (1 M shares), increasing transparency of BriaCell鈥檚 shareholder base.
- None.
Insights
TL;DR: 5.7 % passive stake disclosed; institutional holder presence is neutral-to-slightly positive, no control intentions stated.
The filing introduces CVI/Heights Capital as a mid-sized shareholder, now above the 5 % reporting threshold. Shared, not sole, authority implies a coordinated but non-controlling position. Because the investment is certified as passive, no immediate strategic shift or activist pressure should be expected. From a liquidity perspective, 1 M shares represent modest ownership relative to BriaCell鈥檚 float, signalling limited market impact. Overall, disclosure enhances transparency but is not materially transformational.
TL;DR: Disclosure improves ownership clarity; passive stance lowers governance risk鈥攐verall neutral governance impact.
Schedule 13G confirms the investors鈥� passive status under Rule 13d-1(c), alleviating concerns of an unsolicited takeover attempt. Shared voting/dispositive power is typical for an investment manager structure and aligns with SEC requirements. The disclaimer of beneficial ownership beyond pecuniary interest further limits potential governance influence. No group formation, subsidiary involvement, or control-seeking language appears, suggesting standard institutional investment behaviour.
Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G dichiarando una posizione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La partecipazione rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ogni soggetto dichiarante detiene 0 poteri di voto e disposizione esclusivi e 1.000.000 condivisi. Entrambe le entit脿 escludono la propriet脿 effettiva oltre il loro interesse economico e certificano che le azioni non sono state acquisite per influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o altri interessi di controllo.
El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una posesi贸n pasiva de 1,000,000 acciones ordinarias de BriaCell Therapeutics Corp. (CUSIP 107930208). La participaci贸n equivale al 5.7% de las 17.55 millones de acciones en circulaci贸n, seg煤n el prospecto de BriaCell de julio de 2025. Cada persona informante declara 0 poder de voto y disposici贸n exclusivo y 1,000,000 compartidos. Ambas entidades niegan la propiedad beneficiaria m谩s all谩 de su inter茅s econ贸mico y certifican que las acciones no fueron adquiridas para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se revelan arreglos grupales, subsidiarias ni otros intereses de control adicionales.
2025雲� 7鞗� 15鞚�, CVI Investments, Inc.鞕赌 韴瀽 甏�毽瀽 Heights Capital Management, Inc.電� 瓿惦彊鞙茧 Schedule 13G毳� 鞝滌稖頃橃棳 1,000,000欤� BriaCell Therapeutics Corp. 氤错喌欤� (CUSIP 107930208)鞐� 雽�頃� 靾橂彊鞝� 靻岇湢甓�鞚� 氤搓碃頄堨姷雼堧嫟. 鞚� 歆�攵勳潃 BriaCell鞚� 2025雲� 7鞗� 韴瀽靹る獏靹滌棎 氇呾嫓霅� 17.55氚彪 欤� 欷� 5.7%鞐� 頃措嫻頃╇媹雼�. 臧� 氤搓碃鞛愲姅 雼弲 韴憸 氚� 觳橂秳 甓岉暅 0欤�鞕赌 瓿惦彊 韴憸 氚� 觳橂秳 甓岉暅 1,000,000欤�毳� 欤检灔頃╇媹雼�. 鞏� 旮瓣磤鞚� 旮堨爠鞝� 鞚挫澋鞚� 齑堦臣頃橂姅 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙晿氅�, 欤检嫕鞚� 歆�氚瓣秾 鞓來枼鞚� 氇╈爜鞙茧 旆摑霅橃 鞎婌晿鞚岇潉 鞚胳頃╇媹雼�. 靹滊獏鞛�: Sarah Travis (Heights Capital), 2025雲� 7鞗� 22鞚�. 攴鸽９ 順戩暯, 鞛愴殞靷� 霕愲姅 於旉皜 歆�氚瓣秾鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d'investissement Heights Capital Management, Inc. ont conjointement d茅pos茅 un Schedule 13G d茅clarant une participation passive de 1 000 000 actions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation repr茅sente 5,7 % des 17,55 millions d'actions en circulation, comme indiqu茅 dans le prospectus de BriaCell de juillet 2025. Chaque personne d茅clarante revendique 0 pouvoir de vote et de disposition exclusif et 1 000 000 partag茅. Les deux entit茅s d茅clinent toute propri茅t茅 b茅n茅ficiaire au-del脿 de leur int茅r锚t p茅cuniaire et certifient que les actions n'ont pas 茅t茅 acquises pour influencer le contr么le. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiale ou autre int茅r锚t de contr么le n鈥檈st divulgu茅.
Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein, in dem ein passives Eigentum von 1.000.000 BriaCell Therapeutics Corp. Stammaktien (CUSIP 107930208) gemeldet wurde. Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 ver枚ffentlichten Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verf眉gungsrechte. Beide Einheiten lehnen eine wirtschaftliche Eigent眉merschaft 眉ber ihr finanzielles Interesse hinaus ab und best盲tigen, dass die Aktien nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden. Unterzeichnerin: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.
FAQ
How many BriaCell (BCTXZ) shares do CVI Investments and Heights Capital own?
What percentage of BriaCell鈥檚 outstanding shares does the 1 M-share position represent?
Is the CVI/Heights Capital position passive or activist?
Do CVI Investments or Heights Capital hold sole voting power over the shares?
When was the event triggering the Schedule 13G filing?
